Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA)
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Barretos, Brazil, 14784-400
- Research Site
-
Fortaleza, Brazil, 60336-045
- Research Site
-
Londrina, Brazil, 86015-520
- Research Site
-
Porto Alegre, Brazil, 90610-000
- Research Site
-
Porto Alegre, Brazil, 91350-200
- Research Site
-
Porto Alegre, Brazil, 90110-270
- Research Site
-
Porto Alegre, Brazil, 90050-170
- Research Site
-
Rio de Janeiro, Brazil, 20220-410
- Research Site
-
Sao Paulo, Brazil, 01509-900
- Research Site
-
Sao Paulo, Brazil, 01317-000
- Research Site
-
São José do Rio Preto, Brazil, 15090-000
- Research Site
-
São Paulo, Brazil, 03102-002
- Research Site
-
São Paulo, Brazil, 01246-000
- Research Site
-
-
-
-
-
Antofagasta, Chile, 1267348
- Research Site
-
Santiago, Chile, 7500921
- Research Site
-
Santiago, Chile, 7630370
- Research Site
-
Santiago, Chile, 8380455
- Research Site
-
Temuco, Chile, 4810218
- Research Site
-
Temuco, Chile, 4810469
- Research Site
-
Viña del Mar, Chile, 2540488
- Research Site
-
-
-
-
-
Changchun, China, 130021
- Research Site
-
Changsha, China, 410013
- Research Site
-
Chengdu, China, 610041
- Research Site
-
Chongqing, China, 400030
- Research Site
-
Guangzhou, China, 510000
- Research Site
-
Hangzhou, China, 310022
- Research Site
-
Hefei, China, 230031
- Research Site
-
Hefei, China, 230001
- Research Site
-
Shanghai, China, 200032
- Research Site
-
Shenyang, China, 110016
- Research Site
-
Shenyang, China, 100003
- Research Site
-
Tianjin, China, 300052
- Research Site
-
Wuhan, China, 430079
- Research Site
-
Wuhan, China, 430022
- Research Site
-
-
-
-
-
Budapest, Hungary, 1122
- Research Site
-
Debrecen, Hungary, 4032
- Research Site
-
Győr, Hungary, 9024
- Research Site
-
Kaposvár, Hungary, 7400
- Research Site
-
Szeged, Hungary, 6725
- Research Site
-
-
-
-
-
Ahmedabad, India, 380015
- Research Site
-
Gurgaon, India, 122001
- Research Site
-
Madurai, India, 625107
- Research Site
-
Mumbai, India, 400012
- Research Site
-
Nagpur, India, 440026
- Research Site
-
Nashik, India, 422002
- Research Site
-
New Delhi, India, 110063
- Research Site
-
Vishakhapatnam, India, 530017
- Research Site
-
-
-
-
-
Fukuoka-shi, Japan, 811-1395
- Research Site
-
Kagoshima-shi, Japan, 890-8520
- Research Site
-
Koto-ku, Japan, 135-8550
- Research Site
-
Kyoto-shi, Japan, 606-8507
- Research Site
-
Nakagami-gun, Japan, 903-0215
- Research Site
-
Osaka-shi, Japan, 541-8567
- Research Site
-
Sapporo-shi, Japan, 003-0804
- Research Site
-
Sendai-shi, Japan, 980-8574
- Research Site
-
Shinjuku-ku, Japan, 160-8582
- Research Site
-
Toon-shi, Japan, 791-0204
- Research Site
-
Yokohama-shi, Japan, 236-0004
- Research Site
-
-
-
-
-
Seoul, Korea, Republic of, 03722
- Research Site
-
Seoul, Korea, Republic of, 05505
- Research Site
-
Seoul, Korea, Republic of, 06351
- Research Site
-
Seoul, Korea, Republic of, 08826
- Research Site
-
-
-
-
-
Alc. Cuauhtémoc, Mexico, 06700
- Research Site
-
Deleg. Tlalpan, Mexico, 14080
- Research Site
-
Guadalajara, Mexico, 44680
- Research Site
-
Guadalajara Jalisco, Mexico, 44280
- Research Site
-
Mérida, Mexico, 97134
- Research Site
-
San Luis Potosí, Mexico, 78250
- Research Site
-
Veracruz, Mexico, 91900
- Research Site
-
-
-
-
-
Lima, Peru, L27
- Research Site
-
Lima, Peru, LIMA 27
- Research Site
-
Lima, Peru, LIMA 34
- Research Site
-
Lima, Peru, LIMA 41
- Research Site
-
Lima, Peru, LIMA 31
- Research Site
-
-
-
-
-
Baguio City, Philippines, 2600
- Research Site
-
Cebu, Philippines, 6000
- Research Site
-
Iloilo, Philippines, 5000
- Research Site
-
Makati, Philippines, 1229
- Research Site
-
Manila, Philippines, 1015
- Research Site
-
Quezon City, Philippines, 1112
- Research Site
-
-
-
-
-
Bialystok, Poland, 15-027
- Research Site
-
Gdańsk, Poland, 80-214
- Research Site
-
Gliwice, Poland, 44-101
- Research Site
-
Lublin, Poland, 20-090
- Research Site
-
Łódź, Poland, 90-513
- Research Site
-
-
-
-
-
Arkhangelsk, Russian Federation, 163045
- Research Site
-
Chelyabinsk, Russian Federation, 454087
- Research Site
-
Kaluga, Russian Federation, 248007
- Research Site
-
Moscow, Russian Federation, 115533
- Research Site
-
Moscow, Russian Federation, 125367
- Research Site
-
Moscow, Russian Federation, 117997
- Research Site
-
Novosibirsk, Russian Federation, 630055
- Research Site
-
-
-
-
-
Parktown, South Africa, 2193
- Research Site
-
Port Elizabeth, South Africa, 6045
- Research Site
-
-
-
-
-
Taichung, Taiwan, 40705
- Research Site
-
Tainan City, Taiwan, 704
- Research Site
-
Taipei, Taiwan, 10002
- Research Site
-
Taipei, Taiwan, 10449
- Research Site
-
Taipei, Taiwan, 11490
- Research Site
-
Taipei City, Taiwan, 11217
- Research Site
-
Taoyuan City, Taiwan, 333
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Research Site
-
-
California
-
La Jolla, California, United States, 92093
- Research Site
-
Orange, California, United States, 92868
- Research Site
-
-
Florida
-
Fort Myers, Florida, United States, 33905
- Research Site
-
Miami, Florida, United States, 33136
- Research Site
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Research Site
-
-
New York
-
Bronx, New York, United States, 10461
- Research Site
-
Lake Success, New York, United States, 11042
- Research Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Research Site
-
Cleveland, Ohio, United States, 44111
- Research Site
-
Cleveland, Ohio, United States, 44124
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75390
- Research Site
-
Dallas, Texas, United States, 75235
- Research Site
-
Spring, Texas, United States, 77380
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
For inclusion in the study, patients should fulfill the following criteria:
- Female
- Aged at least 18 years
- Documented evidence of cervical adenocarcinoma or squamous carcinoma FIGO (2009) Stages IB2 to IIB node positive or FIGO (2009) IIIA-IVA any node
- No prior chemotherapy or radiotherapy for cervical cancer
- WHO/ECOG performance status of 0-1
- At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion at baseline.
Exclusion Criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
- Diagnosis of small cell (neuroendocrine) histology or mucinous adenocarcinoma cervical cancer
- Intent to administer a fertility-sparing treatment regimen
- Undergone a previous hysterectomy
- Evidence of metastatic disease per RECIST 1.1 including lymph nodes ≥15 mm (short axis) above the L1 cephalad body, in the inguinal region or outside the planned radiation field.
- History of allogeneic organ transplantation
- Active or prior documented autoimmune or inflammatory disorders
- Uncontrolled intercurrent illness
- History of another primary malignancy and active primary immunodeficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Durvalumab (intravenous infusion)
durvalumab + standard of care concurrent chemoradiation therapy(SoC CCRT) followed by durvalumab monotherapy up to 24 months or until PD from the date of randomization
|
IV infusion every 4 weeks
Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
Radiation therapy per standard of care
|
|
Placebo Comparator: Placebo (matching placebo for intravenous infusion)
placebo + standard of care concurrent chemoradiation therapy(SoC CCRT)
|
Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
Radiation therapy per standard of care
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression
Time Frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
|
PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression
|
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression, PD-L1 Expression >= 1%
Time Frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
|
PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression
|
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
|
|
Objective Response Rate (ORR)
Time Frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
|
Percentage of evaluable patients with an Investigator-assessed visit response of complete response (CR) or partial response (PR).
CR defined as disappearance of all target and non-target lesions and no new lesions.
PR defined as >= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion
|
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
|
|
Complete Response Rate
Time Frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
|
Percentage of evaluable patients with an overall visit response of Complete Response (disappearance of all target and non-target lesions)
|
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
|
|
Duration of Response (DoR) in Patients With Complete Response (CR)
Time Frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
|
Time from date of first documented CR until date of documented progression or death in the absence of progression.
For patients who did not progress their DoR was their Progression-free survival censoring time
|
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
|
|
Overall Survival (Count)
Time Frame: Time from date of randomisation until date of death by any cause, assessed up to the data cut-off date (3rd July 2023), assessed up to a maximum of 51.7 months
|
Number of Participants with Overall Survival (OS) where OS was defined as the time from the date of randomisation until death by any cause
|
Time from date of randomisation until date of death by any cause, assessed up to the data cut-off date (3rd July 2023), assessed up to a maximum of 51.7 months
|
|
Overall Survival (Duration)
Time Frame: Time from date of randomisation until date of death by any cause, assessed up to the data cut-off date (3rd July 2023), assessed up to a maximum of 51.7 months
|
Time from the date of randomisation until death by any cause
|
Time from date of randomisation until date of death by any cause, assessed up to the data cut-off date (3rd July 2023), assessed up to a maximum of 51.7 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with adverse events as assessed by Common Toxicity Criteria for Adverse Events (CTCAE v5.0)
Time Frame: Estimated to be up to 2.5 years
|
Type, frequency and severity of adverse events (including those from the pre- and post-treatment periods) will be listed according to CTCAE v5.0
|
Estimated to be up to 2.5 years
|
|
The safety and tolerability of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by electrocardiograms (ECGs)
Time Frame: Estimated to be up to 2.5 years
|
Resting 12-lead ECGs will be assessed by QTcF interval (ms).
|
Estimated to be up to 2.5 years
|
|
The safety and tolerability of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by vital signs(pulse rate) in beats per minute.
Time Frame: Estimated to be up to 2.5 years
|
Pulse rate will be evaluated according to the schedule of assessments.
|
Estimated to be up to 2.5 years
|
|
The safety and tolerability of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by vital signs(temperature) in degree Celsius.
Time Frame: Estimated to be up to 2.5 years
|
Temperature will be evaluated according to the schedule of assessments.
|
Estimated to be up to 2.5 years
|
|
The safety and tolerability of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by vital signs(respiration rate) in breaths per minute.
Time Frame: Estimated to be up to 2.5 years
|
Respiration rate will be evaluated according to the schedule of assessments.
|
Estimated to be up to 2.5 years
|
|
The safety and tolerability of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by vital signs(blood pressure).
Time Frame: Estimated to be up to 2.5 years
|
Blood pressure will be evaluated according to the schedule of assessments.
|
Estimated to be up to 2.5 years
|
|
The safety and tolerability of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by abnormality in clinical chemistry.
Time Frame: Estimated to be up to 2.5 years
|
Clinical chemistry will be assessed by liver function(Alanine aminotransferase, Aspartate aminotransferase, albumin, total bilirubin), kidney function (e.g.
Urea, Creatinine) and endocrine function(TSH, T3 free,T4 free).
|
Estimated to be up to 2.5 years
|
|
The safety and tolerability of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by abnormality in hematology(cells/L).
Time Frame: Estimated to be up to 2.5 years
|
Hematology will be assessed by white cell count, platelet count, absolute neutrophil count and absolute lymphocyte count.
|
Estimated to be up to 2.5 years
|
|
The safety and tolerability of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by abnormality in hematology(g/L).
Time Frame: Estimated to be up to 2.5 years
|
Hematology will be assessed by haemoglobin.
|
Estimated to be up to 2.5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Urban Scheuring, M.D., Ph.D., AstraZeneca
- Principal Investigator: Bradley Monk, M.D, University of Arizona, Arizona, USA
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Carboplatin
- Durvalumab
Other Study ID Numbers
Other Study ID Numbers
- D9100C00001
- 2018-002872-42 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.